Common Exposure to STL Polyomomavirus During Childhood
Efrem S. Lim, Natalie M. Meinerz, Blake Primi, David Wang, and Robert L. Garcea

STL polyomavirus (STL-VPyV) was recently identified in human specimens. To determine seropositivity for STL-VPyV, we developed an ELISA and screened patient samples from 2 US cities (Denver, Colorado [500]; St. Louis, Missouri [419]). Overall seropositivity was 68%–70%. The age-stratified data suggest that STL-VPyV infection is widespread and commonly acquired during childhood.

Polyomaviruses are nonenveloped double-stranded circular DNA viruses that infect a wide range of hosts, including humans. The capsid of the virus comprises primarily 72 pentamers of the major coat protein, VP1. Human polyomaviruses have been associated with several diseases (1). BK polyomavirus (BKPyV) has been associated with nephropathy in renal transplant recipients and JC polyomavirus (JCPyV) with progressive multifocal leukoencephalopathy in immunocompromised persons (2,3). Trichodysplasia spinulosa–associated polyomavirus (TSPyV) infection is linked to a rare skin disease in immunocompromised persons (4). Furthermore, infection with Merkel cell polyomavirus (MCPyV) in rare instances leads to Merkel cell carcinomas, an aggressive form of skin cancer (5). Other polyomaviruses, including WU polyomavirus (WUPyV), KI polyomavirus (KIPyV), human polyomavirus 6, human polyomavirus 7, human polyomavirus 9, MW polyomavirus (MWPyV), STL polyomavirus (STL-VPyV), and human polyomavirus 12, have been identified in specimens from humans, but their role in disease remains to be defined (1).

Seroepidemiology has played an important role in establishing the link between human polyomaviruses and disease and in understanding infection dynamics. The seroprevalences of BKPyV and JCPyV range from 70% to 90% and 40% to 60%, respectively, with an age profile indicating high frequency of early-age infections and lifelong persistence (6–8). Seropositivity for MCPyV in healthy persons ranges from 25% to 64%; all patients with Merkel cell carcinoma are seropositive (6,9).

STL-VPyV was recently identified from fecal specimens from a child in Malawi (10). Viral DNA also was detected in fecal specimens from the United States and The Gambia, and STL-VPyV has been found in a surface-sanitized skin wart surgically removed from the buttocks of a patient with a primary immunodeficiency called WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome (11). These observations suggest that STL-VPyV might infect humans. We defined the seropositivity rate of STL-VPyV in humans using serum from 2 independent US sites (Denver, Colorado, and St. Louis, Missouri).

The Study
To determine the seropositivity for STL-VPyV, we developed a capture ELISA using recombinant glutathione S-transferase–tagged STL-VPyV VP1 capsomeres (online Technical Appendix, http://wwwnc.cdc.gov/EID/article/20/9/14-0561-Techapp1.pdf). Electron microscopy of the STL-VPyV capsomeres showed 10-nm pentamers characteristic of polyomaviruses (Figure 1, panel A). We assessed the specificity of the STL-VPyV ELISA by pre-incubating 24 serum samples in the presence and absence of soluble STL-VPyV VP1 pentamers before addition to the immobilized STL-VPyV glutathione S-transferase–tagged VP1. The ELISA signal intensity was markedly reduced when serum was pre-incubated with STL-VPyV VP1 pentamers (Figure 1, panel B; compare white bars to gray bars). This result indicates the ELISA seroreactivity could be self-competed with soluble STL-VPyV pentamers. STL-VPyV shares 55% aa identity in the VP1 region with its next most closely related polyomavirus, MWPyV (10). Therefore, we examined whether cross-reactivity existed between STL-VPyV and MWPyV VP1 capsomeres. Competition assays with soluble MWPyV VP1 pentamers showed limited interference with the ELISA seroreactivity (Figure 1, panel C; compare white bars to gray bars). This result indicates that there was no significant cross-reactivity between STL-VPyV and MWPyV VP1 capsomeres. Taken together, these data demonstrate that the ELISA was specific to STL-VPyV VP1.

We screened 500 serum specimens collected from children and adults in Denver for antibodies against STL-VPyV. The overall seropositivity for STL-VPyV was 68.0% (Figure 2, panel A). Children 1–3 years of age had the lowest seropositivity rate (23.8%). In contrast, seroprevalence of children 4–20 years of age ranged from 61.1% to 70.8%. Similar seropositivity rates persisted in adults (>21 years of age), ranging from 68.8% to 74.2%.

We next examined a panel of 419 serum specimens from St. Louis that had a higher resolution of age-stratification in young infants. The overall seropositivity for STL-VPyV was 70.0% (Figure 2, panel B), similar to that...
in the specimens from Denver (68.0%). Seropositivity for STLPyV in infants dropped from 53.3% in the <0.5-year age group to 37.9% in the 0.5–1-year age group, with the lowest seropositivity of 22.6% in the 1–2-year group. In contrast, seropositivity rates for children >2 years of age were higher, ranging from 60.0% to 85.3%. Finally, seropositivity in adults (>21 years of age) ranged from 91.2% to 95.2%. Thus, these data indicate that exposure to STLPyV occurs during early childhood and that immune responses to STLPyV are maintained in adults.

Conclusions

In our analysis of the seroepidemiology of STLPyV in 2 areas of the United States, we found that prevalence of the virus was similar (68.0%–70.0%). This prevalence is slightly higher than the 41.8% for MWPyV, the polyomavirus most closely related to STLPyV (12). However, the seropositivity of STLPyV is comparable to other human polyomaviruses (>60%), such as BKPyV, KIPyV, WUPyV, MCPyV, human polyomavirus 6, and TSPyV (6,8). We found no cross-reactivity with MWPyV VP1, the most closely-related polyomavirus that shares 55% aa identity in the VP1 region. Thus, the seroepidemiology strongly supports the notion that STLPyV is a bona fide infectious agent of humans.

Age stratification of the seropositive specimens suggested an initial waning of immune response followed by rapid seroconversion during childhood. In the St. Louis specimens, seropositivity was higher for the <0.5-year and 0.5–1-year age groups (53.3% and 37.9%, respectively) than for the 1–2-year group (22.6%). This observation was followed by an increase in STLPyV seropositivity in the 2–3-year group and older age groups (60.0%). Specimens from Denver were too few to reliably stratify the data to...
the same resolution. Nonetheless, we observed a similar trend in specimens from Denver where the seropositivity for the 1–3-year age group (23.8%) was lower than for the 4–6-year group (61.1%). These data indicate that immune responses to STLPyV decreased in the first 2 years of age, which suggests waning maternal antibodies. However, seropositivity was rapidly acquired thereafter, indicating high exposure of STLPyV in children. Because the specimens were selected from hospital-associated blood draws of children of unknown health status, seropositivity rates for healthy children might have varied somewhat from the results we obtained. Nonetheless, the trends we observed with STLPyV are similar to profiles that have been reported for JCPyV, BKPyV, TSPyV, MCPyV, WUPyV, and KIPyV (6,13–15).

STLPyV has not been clearly associated with any disease. However, the high overall seropositivity rate suggests widespread infection in the population at large. None of the pathogenic human polyomaviruses (JCPyV, BKPyV, MCPyV, TSPyV) have been clearly associated with acute disease at the time of initial infection. Rather, immunosuppression is a critical co-factor that is coupled to the ability of polyomaviruses to persist throughout life or to integrate into the genome, as in the case of MCPyV, ultimately leading to disease. Our study demonstrates that a large segment of the general population has been infected by STLPyV and might harbor persistent STLPyV infection, assuming the persistence paradigms of JCPyV and BKPyV hold true for STLPyV. A recent report identified STLPyV DNA in a skin wart specimen from an adult with primary immunodeficiency (11). Thus, it is critical to determine whether human diseases exist that are caused by STLPyV, especially in immunocompromised persons.

R.L.G. was supported by National Institutes of Health grant CA37667. D.W. holds an investigator in the pathogenesis of diseases caused by STLPyV, especially in immunocompromised children. Because the specimen was selected from hospital-associated blood draws of children of unknown health status, seropositivity rates for healthy children might have varied somewhat from the results we obtained. Nonetheless, the trends we observed with STLPyV are similar to profiles that have been reported for JCPyV, BKPyV, TSPyV, MCPyV, WUPyV, and KIPyV (6,13–15).

STLPyV has not been clearly associated with any disease. However, the high overall seropositivity rate suggests widespread infection in the population at large. None of the pathogenic human polyomaviruses (JCPyV, BKPyV, MCPyV, TSPyV) have been clearly associated with acute disease at the time of initial infection. Rather, immunosuppression is a critical co-factor that is coupled to the ability of polyomaviruses to persist throughout life or to integrate into the genome, as in the case of MCPyV, ultimately leading to disease. Our study demonstrates that a large segment of the general population has been infected by STLPyV and might harbor persistent STLPyV infection, assuming the persistence paradigms of JCPyV and BKPyV hold true for STLPyV. A recent report identified STLPyV DNA in a skin wart specimen from an adult with primary immunodeficiency (11). Thus, it is critical to determine whether human diseases exist that are caused by STLPyV, especially in immunocompromised persons.

R.L.G. was supported by National Institutes of Health grant CA37667. D.W. holds an investigator in the pathogenesis of infectious disease award from the Burroughs Wellcome Fund. E.S.L. is an Eli and Edythe Broad Fellow of the Life Sciences Research Foundation.

Dr Lim is a postdoctoral research associate at Washington University in St Louis. His research focuses on the discovery and characterization of novel viruses and human pathogens.

References


Address for correspondence: Robert L. Garcea, University of Colorado, School of Medicine, Molecular, Cellular, & Developmental Biology, and The BioFrontiers Institute, Jennie Smoly Caruthers Biotechnology Building, Campus Box 596, Boulder, CO 80309, USA; email: Robert.Garcea@colorado.edu

GovDelivery
Manage your email alerts so you only receive content of interest to you.

Sign up for an online subscription: http://wwwnc.cdc.gov/eid/subscribe.htm
Common Exposure to STL Polyomavirus During Childhood

Technical Appendix

Materials and Methods

Clinical Specimens
A total of 500 serum samples (Denver, CO, USA) were obtained from healthy adult blood donors (May and June 2007) from Bonfils Blood Center (Denver), and serum samples from children were obtained from hospital blood draws at The Children's Hospital (Denver) with the exclusions previously described in (1). The protocols were approved by the Colorado Multiple Institutional Review Board as previously described (1). A total of 419 serum samples (Saint Louis, MO, USA) were obtained from a panel of available serum specimens collected from the clinical laboratories at Barnes-Jewish Hospital (Saint Louis) and St. Louis Children’s Hospital (Saint Louis) (November 2007–October 2008) as previously described (2), using protocols approved by the Human Research Protection Office of Washington University in St. Louis, School of Medicine. Samples were de-identified and analyzed anonymously.

Expression and Purification of Recombinant STL polyomavirus Glutathione S-Transferase–Tagged VP1 Fusion Protein
The \textit{vp1} gene of STL polyomavirus (STLPyV) strain WD972 (GenBank accession no. JX463184) was synthesized (GenScript, Piscataway, NJ, USA) for \textit{Escherichia coli} codon optimization and cloned into pGEX4T3 vector by using BamHI and XhoI restriction sites. N-terminal glutathione S-transferase (GST)–tagged STLPyV VP1 proteins were expressed in \textit{E. coli} and purified by affinity chromatography as previously described (1). STLPyV VP1 capsomeres were prepared by on column cleavage of glutathione-sepharose bound GST VP1 by using thrombin. For electron microscopy, capsomeres were adsorbed onto copper grids and negatively stained with uranyl acetate. Images were captured with a 1Kx1K Gatan Bioscan digital camera on a Philips CM10 electron microscope operating at 80kV.
Capture ELISA

The ELISA was performed as previously described (1). In brief, Polysorp 96-well plates (Nunc, Naperville, IL, USA) were coated with casein-glutathione conjugate overnight at 4°C, after which GST-VP1 (100 ng/well) was bound for 1 h at 4°C. Serum samples were diluted 1:50 in block buffer (5% nonfat dry milk powder; 0.05% Tween 20 in phosphate buffered saline [PBS], pH 7.4) and incubated with the immobilized STLPyV GST-VP1 antigen for 1 h at room temperature, and then washed 3 times with 0.05% Tween 20 in PBS. IgG was detected by using an horseradish peroxidase (HRP)-conjugated secondary antibody (Promega, Madison, WI, USA), and developed with Ultra-tetramethylbenzidine substrate (Thermo Scientific, Waltham, MA, USA). Serum specimens were tested in triplicate. ELISAs for the Denver specimens were performed at University of Colorado Boulder, and ELISAs for the Saint Louis specimens were performed at Washington University. Twenty-eight random serum specimens were tested in both laboratories in a blinded fashion, and ELISA results were concordant in terms of both seropositivity and general intensity trends between both laboratories.

For the competition ELISAs, STLPyV VP1 (3.0 µg/mL) or MWPyV VP1 (manuscript in preparation) (3.0 µg/mL) capsomeres were pre-incubated with 24 serum samples arbitrarily selected across the age distribution (diluted 1:50) for 1 h at 4°C before adding to the immobilized STLPyV GST-VP1 antigen.

ELISA Cutoff Determination

Because ELISAs for the Denver and Saint Louis specimens were performed in separate laboratories, an independent cutoff value was determined for each site. Ranked net absorbance values was plotted and fit to a third-degree polynomial regression model (R^2>0.99). The cutoff value was determined by the inflection point, corresponding to absorbance values of 0.276 (Denver) and 0.239 (Saint Louis).

References
